Trials / Completed
CompletedNCT00002093
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Nexstar Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To compare the toxicity profiles (severity and time to onset from initiation of therapy) between daunorubicin (liposomal) and combination chemotherapy with doxorubicin/bleomycin/vincristine (ABV), with both regimens administered in combination with antiretroviral therapy. To compare the duration of responses, response rates, and times to response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daunorubicin (liposomal) | |
| DRUG | Bleomycin sulfate | |
| DRUG | Vincristine sulfate | |
| DRUG | Doxorubicin hydrochloride |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002093. Inclusion in this directory is not an endorsement.